Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical study of BIO101 (20-hydroxyecdysone) in obesity.
The study will measure muscle strength, mobility and body composition. It is due to start mid-2024 in the United States and could be extended to Europe.
Biophytis expects preliminary results in 2025 and is seeking funding and partnerships to complete the study.
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch